FDA Issues EUA for COVID-19 Treatment
On Monday, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for monoclonal antibody Bamlanivimab for the treatment of mild to moderate COVID-19 in adult and pediatric populations. Bamlanivimab must be administered by intravenous (IV) infusion in non-hospitalized patients. The antibody is being distributed by FDA to state and territorial health departments for allocation to health facilities.
The full EUA approval letter is available here.